Infliximab 5–10 mg/kg vs placebo
Clinical remission · Patients with active Crohn's disease
Infliximab 5–10 mg/kg may leads to higher clinical remission defined as CDAI < 150 at week 4 compared with placebo (low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 4.55 [1.53, 13.5]1 study · 80 participantsLow